Abstract
Aim: Whole genome and peptide mutation analysis can specify effective vaccine and therapeutics against severe acute respiratory coronavirus-2 (SARS-CoV-2). Materials & methods: Whole genome similarity for Bangladeshi SARS-CoV-2 was determined using ClustalW and BLASTn. Phylogenetic analysis was conducted using neighbor-joining method. Results: 100% of isolates in Bangladesh were in the G clade. We found 99.98–100% sequence similarity among Bangladeshi isolates and isolates of England, Greece, USA, Saudi Arabia and India. Deletion of bases at 5′ untranslated region and 3′ untranslated region was detected. Substitution 261 (E→D) at NSP13 and 1109 (F→L) at spike (S) protein were detected. Substitution 377 (D→G) at nucleocapsid with common substitution 614 (D→G) at S were also detected. Conclusion: This study will provide baseline data for development of an effective vaccine or therapeutics against SARS-CoV-2.
Graphical abstract
Author contributions
N Sharif contributed to the writing – original draft preparation (lead); methodology (lead); investigation (lead), conceptualization (lead), formal analysis (lead); writing – review and editing (lead), validation (lead) and data curation (lead). SK Dey was responsible for the conceptualization (lead), funding acquisition (lead), project administration (lead), resources (lead) and supervision (lead).
Acknowledgments
The authors are thankful to the Faculty members of Department of Microbiology, Jahangirnagar University for their support.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.